Devi Nair, MD, director of cardiac electrophysiology at St. Bernard's Healthcare, Jonesboro, Arkansas, explains some of the recent advances in transcatheter left atrial appendage (LAA) occlusion technology at the 2022 Transcatheter Valve Therapeutics (TVT) Structural Heart Summit.

According to a new SCAI statement, the FDA's recommendation would result in "far-reaching consequences" across multiple specialties. 

It was clear at TVT that tricuspid valve therapies will likely move ahead of new mitral therapies coming to market. Azeem Latib, MD, explained why.

A new study to examine the relationship between extreme-heat events and cardiovascular mortality found that the hottest days can indeed be deadly.

One thing was clear at TVT 2022 in Chicago: TAVR's popularity over surgery is changing the way physicians think about patient care. 

This latest recall involves the device's batteries, which are separating due to a "welding defect." 

Here are links to more information for all the late-breaking presentations at the 2022 Transcatheter Valve Therapies (TVT) Structural Heart Summit.

Charles Davidson, MD, clinical chief of cardiology and medical director of the Bluhm Cardiovascular Institute, Northwestern University, explains what hospitals need to consider when starting a new structural heart program. 

The majority of patients undergoing stress tests have symptoms consistent with obstructive coronary artery disease.

Detecting plaque erosion can offer an early warning sign of restricted blood flow to the heart, which can cause heart attacks.